Enzolytics Inc (ENZC)
Enzolytics Inc. is a biotechnology company focused on developing and commercializing proprietary protein-based therapies for debilitating infectious diseases. Its research has centered on patented anti-HIV therapeutics and a method for producing human IgG1 monoclonal antibodies intended for non-toxic passive immunotherapy. The company has also reported clinical testing of its anti-HIV therapeutic candidates. In addition, Enzolytics says its proprietary cell line is designed to produce human monoclonal antibodies that target and neutralize the HIV virus. The company is based in Plano, Texas, and its common stock trades on OTC Markets under the symbol ENZC.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Market Cap |
|---|---|---|---|---|---|---|
|
OTC-ENZC
|
Not available
|
Not available
|
Not available
|
Weak
|
0.0%
|
1.449 M
|